Biomea Fusion Receives Buy Rating from D. Boral Capital

Got story updates? Submit your updates here. ›

Biomea Fusion (NASDAQ:BMEA) received a 'buy' rating and a $12.00 price target from D. Boral Capital, a research firm, in a note issued to investors on Wednesday. The rating comes as Biomea Fusion continues to advance its lead clinical asset, BMF-219, an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction.

Why it matters

Biomea Fusion is a clinical-stage biopharmaceutical company focused on developing small molecule therapies that target epigenetic regulators implicated in cancer. The 'buy' rating and price target from D. Boral Capital suggest analysts see significant potential in the company's pipeline, particularly its lead candidate BMF-219, which is being evaluated for the treatment of hematological malignancies and solid tumors.

The details

In their research note, analysts at D. Boral Capital reiterated a 'buy' rating and $12.00 price target on Biomea Fusion's stock. This comes as the company continues to advance the development of BMF-219, its lead clinical asset. BMF-219 is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction, which plays a key role in the initiation and progression of certain cancers.

• Biomea Fusion's stock price opened at $1.90 on Wednesday, April 8, 2026.
• The company's 50-day moving average price is $1.32, and its 200-day moving average price is $1.40.

What’s next

Investors will be closely watching Biomea Fusion's progress as it continues to advance the development of its lead candidate, BMF-219, for the treatment of hematological malignancies and solid tumors.